Polymyositis, a very uncommon isolated disease: clinical and histological re-evaluation after long-term follow-up

Rheumatology International

Volumn 35, Issue 5, 2015, Pages 915-920

  Vilela, Veronica Silva ^a,b   Prieto González, Sergio ^b   Milisenda, José C ^b   Selva O'Callaghan, Albert ^c   Grau, Josep M ^b  

^a HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Connective tissue disease; Idiopathic inflammatory myopathy; Inclusion body myositis; Necrotizing autoimmune myopathy; Polymyositis

Indexed keywords

ADULT; AGED; AUTOIMMUNE DISEASES; COHORT ANALYSIS; COMPLICATION; CONNECTIVE TISSUE DISEASES; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FACTUAL DATABASE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MYOSITIS; MYOSITIS, INCLUSION BODY; NEOPLASMS; PATHOLOGY; POLYMYOSITIS; RETROSPECTIVE STUDY; SKELETAL MUSCLE; VIRUS DISEASES; YOUNG ADULT;

ADULT; AGED; AUTOIMMUNE DISEASES; COHORT STUDIES; CONNECTIVE TISSUE DISEASES; DATABASES, FACTUAL; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS; MYOSITIS, INCLUSION BODY; NEOPLASMS; POLYMYOSITIS; RETROSPECTIVE STUDIES; VIRUS DISEASES; YOUNG ADULT;

EID: 84940002799     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-3198-5     Document Type: Article

References (30)

1. Milisenda JC, Selva-´Callaghan A, Grau JM (2014) The diagnosis and classification of polymyositis. J Autoimmun 48–49:118–121
2. Amato AA, Griggs RC (2003) Unicorns, drag dragons, polymyositis and other mythological beasts. Neurology 61:288–290
3. Van Der Meulen MFG, Bronner IM, Hoogendijk JE et al (2003) Polymyositis: an overdiagnosed entity. Neurology 61:316–321
4. Kissel JT (2008) Polymyositis: not a unicorn or mythological beast…but maybe a duck ? Neurology 70:414–415
5. Chahin N, Engel (2008) Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70:418–424
6. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis: first of two parts. N Engl J Med 292:344–347
7. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis: second of two parts. N Engl J Med 292:403–407
8. Heckmann JM, Pillay K, Hearn AP, Kenyon C (2010) Polymyositis in HIV-infected subjects. Neuromuscul Disord 20:735–739
9. Aydintug A, Cervera R, D´Cruz D, Rammírez G et al (1991) Polymyositis complicating D-penicillamine treatment. Postgrad Med 67:1018–1020
10. Ishikawa Y, Yukawa N, Ohmura K et al (2009) Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis:a case report and review of literature. Clin Rheumatol 29:563–566
11. Vint J, Samson M, Galtier JN et al (2010) Dysferlin deficiency treated like refractory polymyositis. Clin Rheumatol 29:103–106
12. Chapin JE, Kornfeld M, Harris A (2005) Amyloid myopathy: characteristic features of a still underdiagnosed disease. Muscle Nerve 31:266–272
13. Tang YC, Wang SK, Yuan WL, Tang YC, Wang SK (2011) Primary aldosteronism simulating polymyositis. J Rheumatol 38:1529–1533
14. Yunis EJ, Samaha FJ (1971) Inclusion body myositis. Lab Invest 25:240–248
15. Milisenda JC, Prieto-Gonzáles S, Grau JM (2012) Sporadic inclusion body myositis. Semin Fund Esp Reumatol 13:23–30
16. Miller T, Al-Tozi MT, Lopate G, Pestronk A (2002) Myopathy with antibodies to signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psichiatr 73:420–428
17. Vargas-Leguás H, Selva-O´Callaghan A, Campins-Martí M et al (2007) Polymyositis-dermatomyositis: incidence in Spain (1997–2004). Med Clin (Barc) 129:721–724
18. Prieto S, Grau JM (2010) The geoepidemiology of autoimmune muscle disease. Autoimmun Rev 9:A330–A334
19. TroyanovY Tragoff I, Tremblay JL, Goulet JR, Raymond Y, Senécal JL (2005) Novel classification of idiopathic inflammatory myositis based on overlap syndrome features and autoantibodies. Analysis of 100 French–Canadian patients. Medicine (Baltimore) 84:231–249
20. D´Arcy CE, Ryan MM, McLean CA (2009) Juvenile polymyositis or paediatric muscle dystrophy: a detailed re-analysis of 13 cases. Hystopathology 55:452–462
21. Fernandez C, Bardin N, De Paula AM, Salort-Campana E, Beyamine A, Franques J et al (2013) Correlation of clinicoserologic and pathologic classifications on inflammatory myopathies. Medicine (Baltimore) 92:15–24
22. Carpenter S, Karpati G (2001) Pathology of skeletal muscle, 2nd edn., Oxford University Press, Oxford, ISBN: 0-19506364-3
23. Dalakas M, Hohfeld R (2003) Polymyositis and dermatomyositis. Lancet 362:971–982
24. Griggs RC, Askanas V, Di Mauro S, Engel A, Karpati G, Mendell G et al (1995) Inclusion body myositis. Ann Neurol 38:705–713
25. Averbuch Heller L, Steiner I, Abramsky O (1992) Neurologic manifestations of progressive systemic sclerosis. Arch Neurol 49:1292–1295
26. Clements PJ, Furst DE, Campion DS et al (1978) Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arhtritis Rheum 21:62–71
27. Ranque B, Authier F-J, Le-Guern V et al (2009) A descriptive and prognostic study of systemic sclerosis-associated myopathies. Ann Rheum Dis 68:1474–1477
28. Meyer A, Meyer N, Schaeffer M, Gottemberg JE, Geny B, Sibilia J (2014) Incidence and prevalence of idiopathic myopathies: a systematic review. Rheumatology 26:261–275
29. Tan JA, Roberts-Thompson PJ, Blumbergs P, Hakendorf P, Cox SR, Limaye V (2013) Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30 years epidemiologic study of biopsy proven cases. Int J Rheum Dis 16:331–338
30. Linklater H, Pipetone N, Rose MR et al (2013) Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumtol 31:767–769